Complement system in dermatological diseases - Fire under the skin

Frontiers in Medicine

Volumn 2, Issue JAN, 2015, Pages

  Panelius, Jaana ^a,b   Meri, Seppo ^a,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Complement deficiency; Complement evasion; Hereditary and acquired angioedema; Partial lipodystrophy; Pemphigoid; Pemphigus; Systemic lupus erythematosus; Vasculitic syndromes

Indexed keywords

EID: 84978690867     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak-Rothstein A, Abbas AK. Response to self antigen imprints regulatory memory in tissues. Nature (2012) 480:538-42. doi:10.1038/nature10664
2. Timár KK, Pasch MC, Norbert HA, van der Bosch NHA, Jarva H, Junnikkala S, et al. Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-γ. Mol Immunol (2006) 43:317-25. doi:10.1016/j.molimm.2005.02.009
3. Timár KK, Junnikkala S, Dallos A, Jarva H, Bhuiyan ZA, Meri S, et al. Human keratinocytes produce the complement inhibitor factor I: synthesis is regulated by interferon-gamma. Mol Immunol (2007) 44:2943-9. doi:10.1016/j.molimm.2007.01.007
4. Riihilä PM, Nissinen LM, Ala-Aho R, Kallajoki M, Grenman R, Meri S, et al. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol (2014) 134:498-506. doi:10.1038/jid.2013.346
5. Timár KK, Dallos A, Kiss M, Husz S, Bos JD, Asghar SS. Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 44:2578-86. doi:10.1016/j.molimm.2006.12.014
6. Basset-Seguin N, Caughman SW, Yancey KB. A-431 cells and human keratinocytes synthesize and secrete the third component of complement. J Invest Dermatol (1990) 95:621-5. doi:10.1111/1523-1747.ep12513524
7. Yancey KB, Overholser O, Domloge-Hultsch N, Li LJ, Caughman SW, Bisalbutra P. Human keratinocytes and A-431 cells synthesize and secrete factor B, the major zymogen protease of the alternative complement pathway. J Invest Dermatol (1992) 98:379-83. doi:10.1111/1523-1747.ep12499812
8. Dovezenski N, Billetta R, Gigli I. Expression and localization of proteins of the complement system in human skin. J Clin Invest (1992) 90:2000-12. doi:10.1172/JCI116080
9. Asghar SS, Timár KK, Pasch MC. Complement as a part of the skin immune system. In: Bos JD, editor. Skin Immune System. Boca Raton, FL: CRC Press (2005). p. 327-48
10. Fayyazi A, Sandau R, Duong LQ, Gotze O, Radzun HJ, Schweyer S, et al. C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol (1999) 154:495-501. doi:10.1016/S0002-9440(10)65295-9
11. Pasch MC, Bos JD, Daha MR, Asghar SS. Transforming growth factor-beta isoforms regulate the surface expression of membrane cofactor protein (CD46) and CD59 on human keratinocytes. Eur J Immunol (1999) 29:100-8. doi:10.1002/(SICI)1521-4141(199901)29:01<100::AID-IMMU100>3.3.CO;2-I
12. Katz Y, Strunk RC. Enhanced synthesis of factor B induced by tumor necrosis factor in human skin fibroblasts is decreased by IL-4. J Immunol (1990) 12:4675-80
13. Katz Y, Strunk RC. Synthesis and regulation of complement protein factor H in human skin fibroblasts. J Immunol (1988) 2:559-63
14. Al-Adnani MS, McGee JOD. C1q production and secretion by fibroblasts. Nature (1976) 263:145-6. doi:10.1038/263145a0
15. Garred P, Hetland G, Mollnes TE, Stoervold G. Synthesis of C3, C5, C6, C7, C8 and C9 by human fibroblasts. Scand J Immunol (1990) 32:555-60. doi:10.1111/j.1365-3083.1990.tb03196.x
16. Gulati P, Lemercier C, Gud D, Lappin D, Whaley K. Regulation of the synthesis of C1 subcomponents and C1-inhibitor. Behring Inst Mitt (1993) 93:196-203
17. Loos M, Martin H, Petry F. The biosynthesis of C1q, the collagen-like and Fc-recognizing molecule of the complement system. Behring Inst Mitt (1989) 84:32-41
18. Würzner R, Joysey VC, Lachmann PJ. Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. J Immunol (1994) 152:4624-9
19. Werth VP, Ivanov IE, Nussenzweig V. Decay-accelerating factor is associated with elastic fibers. J Invest Dermatol (1988) 91:511-6. doi:10.1111/1523-1747.ep12476743
20. Sayama K, Shiraishi S, Shirakata Y, Kobayashi Y, Miki Y. Characterization of decay-accelerating factor (DAF) in human skin. J Invest Dermatol (1991) 96:61-4. doi:10.1111/1523-1747.ep12514737
21. Dahlbäck K, Löfberg H, Dahlbäck B. Localization of vitronectin (S-protein of complement) in normal human skin. Acta Derm Venereol (1986) 66:461-7
22. Tagami H. The role of complement-derived mediators in inflammatory skin diseases. Arch Dermatol Res (1992) 284:S2-9. doi:10.1007/BF00638232
23. Silverman GA. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem (2001) 276:33293-6. doi:10.1074/jbc.R100016200
24. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med (2009) 15:69-78. doi:10.1016/j.molmed.2008.12.001
25. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet (2000) 356:213-7. doi:10.1016/S0140-6736(00)02483-1
26. Cichon S, Martin L, Hennies HC, Müller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet (2006) 79:1098-104. doi:10.1086/509899
27. Banerji A, Scheffer AL. The spectrum of chronic angioedema. Allergy Asthma Proc (2009) 30:11-6. doi:10.2500/aap.2009.30.3188
28. Frank MM. Complement disorders and hereditary angioedema. J Allergy Clin Immunol (2010) 125:S262-71. doi:10.1016/j.jaci.2009.10.063
29. Alsenz J, Lambris JD, Bork K, Loos M. Acquired C1-inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. J Clin Invest (1989) 83:1794-9. doi:10.1172/JCI114084
30. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am (2006) 26:669-90. doi:10.1016/j.iac.2006.08.002
31. Yang Y, Chung EK, Zhou B, Lhotta K, Hebert LA, Birmingham DJ, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun (2004) 7:98-132. doi:10.1159/000075689
32. Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology (1999) 42:47-52. doi:10.1016/S0162-3109(99)00018-1
33. Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet (1998) 19:56-9. doi:10.1038/ng0598-56
34. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol (2004) 22:431-56. doi:10.1146/annurev.immunol.22.012703.104549
35. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens are generated during apoptosis. J Exp Med (1995) 181:1557-61. doi:10.1084/jem.181.4.1557
36. Antes U, Heinz HP, Loos M. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum (1988) 31:457-64. doi:10.1002/art.1780310401
37. Tsacheva I, Radanova M, Todorova N, Argirova T, Kishore U. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol Immunol (2007) 44:2157-61. doi:10.1016/j.molimm.2006.09.009
38. Hoekzema R, Hannema AJ, Swaak TJ, Paardekooper J, Hack CE. Low molecular weight C1q in systemic lupus erythematosus. J Immunol (1985) 135:265-71
39. Mészáros T, Furst G, Farkas H, Jakab L, Temesszentandrási G, Nagy G, et al. C1-inhibitor autoantibodies in SLE. Lupus (2010) 19:634-8. doi:10.1177/0961203309357059
40. Seelen MA, Trouw LA, van der Hoorn JWA, Fallaux-van der Houten FC, Huizinga TWJ, Daha MR, et al. Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol (2003) 134:335-43. doi:10.1046/j.1365-2249.2003.02274.x
41. Jönsen A, Bengtsson AA, Sturfelt G, Truedsson L. Analysis of HLA DR, HLA DQ, C4A, Fcgamma RIIa, Fcgamma RIIIA, MBL and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of combined Fcgamma RIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Res Ther (2004) 6:R557-62. doi:10.1186/ar1224
42. Dauchel H, Joly P, Delpech A, Thomine E, Sauger F, Le Loet X. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3dg and terminal complement complex as sensitive markers. Clin Exp Immunol (1993) 92:274-83. doi:10.1111/j.1365-2249.1993.tb03392.x
43. Kawana S, Shen GH, Kobayashi Y, Nishiyama S. Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephritis. Arch Dermatol Res (1990) 282:183-7. doi:10.1007/BF00372620
44. Magro CM, Crowson AN, Harrist TJ. The use of antibody to C5b-9 in the subclassification of lupus erythematosus. Br J Dermatol (1996) 134:855-62. doi:10.1046/j.1365-2133.1996.117852.x
45. Bossi F, Peerschke EI, Ghebrehiwet B, Tedesco F. Cross-talk between the complement and the kinin system in vascular permeability. Immunol Lett (2011) 140:7-13. doi:10.1016/j.imlet.2011.06.006
46. Karpman D, Kahn R. The contact/kinin and complement systems in vasculitis. APMIS (2009) 117(Suppl 127):48-54. doi:10.1111/j.1600-0463.2009.02477.x
47. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol (2007) 170:52-64. doi:10.2353/ajpath.2007.060573
48. Jara LJ, Navarro C, Medina G, Vera-Lastra O, Saavedra MA. Hypocomplementemic urticarial vasculitis syndrome. Curr Rheumatol Rep (2009) 11:410-5. doi:10.1007/s11926-009-0060-y
49. Kallenberg CG. Anti-C1q antibodies. Autoimmun Rev (2008) 8:612-5. doi:10.1016/j.autrev.2008.06.006
50. Her MY, Song JY, Kim DY. Hypocomplementemic urticarial vasculitis in systemic lupus erythematosus. J Korean Med Sci (2009) 24:184-6. doi:10.3346/jkms.2009.24.1.184
51. Femiano F. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis. Minerva Stomatol (2007) 56:215-23
52. Cirillo N, Cozzani E, Carrozzo M, Grando SA. Urban legends: pemphigus vulgaris. Oral Dis (2012) 18:442-58. doi:10.1111/j.1601-0825.2011.01899.x
53. Jordon RE, Kawana S, Fritz KA. Immunopathologic mechanisms in pemphigus and bullous pemphigoid. J Invest Dermatol (1985) 85:72s-8s. doi:10.1111/1523-1747.ep12275497
54. Kawana S, Georghegan WD, Jordon RE, Nishiyama S. Deposition of the membrane attack complex of complement in pemphigus vulgaris and pemphigus foliaceus skin. J Invest Dermatol (1989) 92:588-92. doi:10.1111/1523-1747.ep12709624
55. Sitaru C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res (2007) 299:1-8. doi:10.1007/s00403-007-0734-0
56. Powell AM, Sakuma-Oyama Y, Oyama N, Black MM. Collagen XVII/BP180: a collagenous transmembrane protein and component of the dermoepidermal anchoring complex. Clin Exp Dermatol (2005) 30:682-7. doi:10.1111/j.1365-2230.2005.01937.x
57. Ujiie H, Shibaki A, Nishie W, Shimizu H. What's new in bullous pemphigoid. J Dermatol (2010) 37:194-204. doi:10.1111/j.1346-8138.2009.00792.x
58. Liu Z. Immunopathology of bullous pemphigoid, an autoimmune and inflammatory skin blistering disease. Keio J Med (2003) 52:128-33. doi:10.2302/kjm.52.128
59. Lessey E, Li N, Diaz L, Liu Z. Complement and cutaneous autoimmune blistering diseases. Immunol Res (2008) 41:223-32. doi:10.1007/s12026-008-8028-y
60. Martinez-De Pablo MI, González-Enseñat MA, Vicente A, Gilabente M, Mascaro JM. Childhood bullous pemphigoid: clinical and immunological findings in a series of 4 cases. Arch Dermatol (2007) 143:215-20
61. Preisz K, Sárdy M, Horváth A, Kárpáti S. Immunoglobulin, complement and epidermal transglutaminase deposition in the cutaneous vessels in dermatitis herpetiformis. J Eur Acad Dermatol Venereol (2005) 19:74-9
62. Levy Y, George J, Yona E, Schoenfeld Y. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. Immunol Res (1998) 18:55-60. doi:10.1007/BF02786513
63. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 16:1392-403. doi:10.1681/ASN.2005010078
64. Cronin CC, Higgins T, Molloy M. Lupus, C3 nephritic factor and partial lipodystrophy. Q J Med (1995) 88:298-9
65. Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. Clin Exp Immunol (1989) 76:82-5
66. Savage DB, Semple RK, Clatworthy MR, Lyons PA, Morgan BP, Cochran EK, et al. Complement abnormalitis in acquired lipodystrophy revisited. J Clin Endocrinol Metab (2009) 94:10-6. doi:10.1210/jc.2008-1703
67. Morgan BP. Complement. Clinical Aspects and Relevance to Disease. London: Academic Press, Harcourt Brace Jovanovich (1990)
68. Kallio-Laine K, Seppänen M, Aittoniemi J, Kautiainen H, Seppälä I, Valtonen V, et al. HLA-DRB1*01 allele and low plasma immunoglobulin G1 concentration may predispose to herpes-associated recurrent lymphocytic meningitis. Hum Immunol (2010) 71:179-81. doi:10.1016/j.humimm.2009.10.014
69. Bathum L, Hansen H, Teisner B, Koch C, Garred P, Rasmussen K, et al. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol (2006) 43:473-9. doi:10.1016/j.molimm.2005.02.017
70. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM. Interactions between Neisseria meningitidis and the complement system. Trends Microbiol (2007) 15:233-40. doi:10.1016/j.tim.2007.03.005
71. Fingerle V, Schulte-Spechtel U, Ruzic-Sabljic E, Leonhard S, Hofmann H, Weber K, et al. Epidemiological aspects and molecular characterization of Borrelia burgdorferi s.l. from southern Germany with special respect to the new species Borrelia spielmanii sp. nov. Int J Med Microbiol (2008) 298:279-90. doi:10.1016/j.ijmm.2007.05.002
72. Ruzic-Sabljic E, Zore A, Strle F. Characterization of Borrelia burgdorferi sensu lato isolates by pulsed-field gel electrophoresis after M1uI restriction of genomic DNA. Res Microbiol (2008) 159:441-8. doi:10.1016/j.resmic.2008.05.005
73. Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet (2012) 379:461-73. doi:10.1016/S0140-6736(11)60103-7
74. Alitalo A, Meri T, Rämö L, Jokiranta TS, Heikkilä T, Seppälä IJT, et al. Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation. Infect Immun (2001) 69:3685-91. doi:10.1128/IAI.69.6.3685-3691.2001
75. Hellwage J, Meri T, Heikkilä T, Alitalo A, Panelius J, Lahdenne P, et al. The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J Biol Chem (2001) 276:8427-35. doi:10.1074/jbc.M007994200
76. Kraiczy P, Skerka C, Kirschfink M, Zipfel PF, Brade V. Mechanism of complement resistance of pathogenic Borrelia burgdorferi isolates. Int Immunopharmacol (2001) 1:393-401. doi:10.1016/S1567-5769(00)00041-2
77. Pietikäinen J, Meri T, Blom AM, Meri S. Binding of the complement inhibitor C4b-binding protein to Lyme disease Borreliae. Mol Immunol (2010) 47:1299-305. doi:10.1016/j.molimm.2009.11.028
78. Panelius J, Ranki A, Meri T, Seppälä I, Meri S. Expression and sequence diversity of the complement regulating outer surface protein E in Borrelia afzelii vs. B. garinii in patients with erythema migrans or neuroborreliosis. Microb Pathog (2010) 49:363-8. doi:10.1016/j.micpath.2010.06.006
79. Brooks CS, Vuppala SR, Jett AM, Alitalo A, Meri S, Akins DA. Complement regulator acquiring surface protein 1 (CRASP-1) imparts resistance to human serum in B. burgdorferi. J Immunol (2005) 175:3299-308. doi:10.4049/jimmunol.175.5.3299
80. Kenedy MR, Vuppala SR, Siegel C, Kraiczy P, Akins DR. CspA-mediated binding of human factor H inhibits complement deposition and confers serum resistance in Borrelia burgdorferi. Infect Immun (2009) 77:2773-82. doi:10.1128/IAI.00318-09
81. Alitalo A, Meri T, Lankinen H, Seppälä I, Lahdenne P, Hefty PS, et al. Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol (2002) 169:3847-53. doi:10.4049/jimmunol.169.7.3847
82. Stevenson B, El-Hage N, Hines MA, Miller JC, Babb K. Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect Immun (2002) 70:491-7. doi:10.1128/IAI.70.2.491-497.2002
83. Alitalo A, Meri T, Cheng T, Lankinen H, Cheng Z-Z, Jokiranta TS, et al. Lysine-dependent multipoint binding of the Borrelia burgdorferi virulence factor outer surface protein E to the C terminus of factor H. J Immunol (2004) 172:6195-201. doi:10.4049/jimmunol.172.10.6195
84. Fischetti VA, Horstmann RD, Pancholi V. Location of the complement factor H binding site on streptococcal M6 protein. Infect Immun (1995) 63:149-53
85. Thern A, Stenberg L, Dahlbäck B, Lindahl G. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J Immunol (1995) 154:375-86
86. Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A (1985) 82:8144-8. doi:10.1073/pnas.82.23.8144
87. Jarva H, Jokiranta S, Wurzner R, Meri S. Complement resistance mechanisms of streptococci. Mol Immunol (2003) 40:95-107. doi:10.1016/S0161-5890(03)00108-1
88. Haapasalo K, Vuopio J, Syrjänen J, Suvilehto J, Massinen S, Karppelin M, et al. Acquisition of complement factor H is important for pathogenesis of Streptococcus pyogenes infections: evidence from bacterial in vitro and human genetic association. J Immunol (2012) 188:426-35. doi:10.4049/jimmunol.1102545
89. Lewy FD. Staphylococcus aureus infections. N Engl J Med (1998) 339:520-32. doi:10.1056/NEJM199808203390806
90. Amdahl H, Jongerius I, Meri T, Pasanen T, Hyvärinen S, Haapasalo K, et al. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion. J Immunol (2013) 191:1775-84. doi:10.4049/jimmunol.1300638
91. Haupt K, Reuter M, van der Elsen J, Burman J, Hälbich S, Richter J, et al. The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement factor H and C3b. PLoS Pathog (2008) 4:e1000250. doi:10.1371/journal.ppat.1000250
92. Shannon O, Uekotter A, Flock JI. Extracellular fibrinogen binding protein, Efb, from Staphylococcus aureus as an antiplatelet agent in vivo. Thromb Haemost (2005) 93:927-31
93. Lee LY, Liang X, Höök M, Brown EL. Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb). J Biol Chem (2004) 279:50710-6. doi:10.1074/jbc.M408570200
94. Chen H, Ricklin D, Hammel M, Garcia BL, McWhorter WJ, Sfyroera G, et al. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc. Natl Acad Sci U S A (2010) 107:17621-6. doi:10.1073/pnas.1003750107
95. Ko Y-P, Kuipers A, Freitag CM, Jongerius I, Medina E, van Rooijen WJ, et al. Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface. PLoS Pathog (2013) 9:e1003816. doi:10.1371/journal.ppat.1003816
96. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy (2008) 63:751-7. doi:10.1111/j.1398-9995.2007.01577.x
97. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol (2009) 124:801-8. doi:10.1016/j.jaci.2009.07.017
98. Nurnberger W, Heying R, Burdach S, Göbel U. C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol (1997) 75:95-101. doi:10.1007/s002770050321
99. Antonen J, Leppänen I, Tenhunen J, Arvola P, Mäkelä S, Vaheri A, et al. A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Scand J Infect Dis (2013) 45:494-6. doi:10.3109/00365548.2012.755268
100. Parker CJ, Kar S, Kirkpatrick P. Fresh from the pipeline: eculizumab. Nat Rev Drug Discov (2007) 6:515-6. doi:10.1038/nrd2369
101. Chapin J, Weksler B, Magro C, Laurence J. Ecilizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol (2012) 157:762-74. doi:10.1111/j.1365-2141.2012.09084.x
102. Meri S, Jördens M, Jarva H. Microbial complement inhibitors as vaccines. Vaccine (2008) 26S:I113-7. doi:10.1016/j.vaccine.2008.11.058